Low extracellular vesicle concentrations predict survival in patients with heart failure.
| Autor: | Schöler D; Clinic for Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University Düsseldorf, Düsseldorf, Germany., Loosen SH; Clinic for Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University Düsseldorf, Düsseldorf, Germany., Wirtz TH; Department of Gastroenterology, Digestive Diseases and Intensive Care Medicine, RWTH Aachen University Hospital, Aachen, Germany., Brozat JF; Department of Gastroenterology, Digestive Diseases and Intensive Care Medicine, RWTH Aachen University Hospital, Aachen, Germany.; Department of Hepatology and Gastroenterology, Charite-Universitätsmedizin Berlin Campus Virchow-Klinikum (CVK) and Campus Charite Mitte (CCM), Berlin, Germany., Dos Santos Ferreira Grani LA; Clinic for Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University Düsseldorf, Düsseldorf, Germany., Luedde T; Clinic for Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University Düsseldorf, Düsseldorf, Germany., Heinrichs L; Clinic for Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University Düsseldorf, Düsseldorf, Germany., Frank D; Internal Medicine III, University Hospital of Schleswig Holstein, Campus Kiel, Kiel, Germany., Koch A; Department of Gastroenterology, Digestive Diseases and Intensive Care Medicine, RWTH Aachen University Hospital, Aachen, Germany., Roderburg C; Clinic for Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University Düsseldorf, Düsseldorf, Germany., Spehlmann ME; Internal Medicine III, University Hospital of Schleswig Holstein, Campus Kiel, Kiel, Germany. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Frontiers in cardiovascular medicine [Front Cardiovasc Med] 2023 May 24; Vol. 10, pp. 1163525. Date of Electronic Publication: 2023 May 24 (Print Publication: 2023). |
| DOI: | 10.3389/fcvm.2023.1163525 |
| Abstrakt: | Background: Heart disease is of worldwide importance due to high morbidity and mortality. Extracellular vesicle (EV) concentration and size represent novel diagnostic and prognostic biomarkers, e.g. in patients with liver cancer, but data on their prognostic relevance in heart disease are lacking. Here, we investigated the role of EV concentration, size and zeta potential in patients with heart disease. Methods: Vesicle size distribution, concentration and zeta potential were measured by nanoparticle tracking analysis (NTA) in 28 intensive care unit (ICU) and 20 standard care (SC) patients and 20 healthy controls. Results: Patients with any disease had a lower zeta potential compared to the healthy controls. Vesicle size (X50) was significantly higher in ICU patients (245 nm) with heart disease as compared to those patients with heart disease receiving standard care (195 nm), or healthy controls (215 nm) ( p = 0.001). Notably, EV concentration was lower in ICU patients with heart disease (4.68 × 10 10 particles/ml) compared to SC patients with heart disease (7,62 × 10 10 particles/ml) and healthy controls (1.50 × 10 11 particles/ml) ( p = 0.002). Extracellular vesicle concentration is prognostic for overall survival in patients with heart disease. Overall survival is significantly reduced when the vesicle concentration is below 5.55 × 10 10 particles/ml. Median overall survival was only 140 days in patients with vesicle concentrations below 5.55 × 10 10 particles/ml compared to 211 days in patients with vesicle concentrations above 5.55 × 10 10 particles/ml ( p = 0.032). Summary: Concentration of EVs is a novel prognostic marker in ICU and SC patients with heart disease. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (© 2023 Schöler, Loosen, Wirtz, Brozat, dos Santos Ferreira Grani, Luedde, Heinrichs, Frank, Koch, Roderburg and Spehlmann.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|